Table 3. Demographic, epidemiological and clinical characteristics of MDR-TB or XDR-TB cases included in systematic review according to linezolid dose.
| Variables | Total | LNZ ≤600 mg/day | LNZ >600 mg/day | P value |
|---|---|---|---|---|
| Number of patients included | 367 | 151 | 216 | – |
| Male, n (%) | 143/266 (53.8) | 80/151 (53.0) | 63/115 (54.8) | 0.77 |
| Types of countries | ||||
| Developed countries (%) | 285/367 (77.7) | 115/151 (76.2) | 170/216 (78.7) | 0.56 |
| Developing countries (%) | 82/367 (22.3) | 36/151 (23.8) | 46/216 (21.3) | – |
| Median (IQR) age at the admission, years | 35.3 (24.0-41.2) | 36.2 (29.0-41.2) | 34.6 (24.0-40.0) | 0.608 |
| HIV-positive, n (%) | 14/171 (8.2) | 14/113 (12.4) | 0/58 (0.0) | 0.005 |
| Surgical treatment, n (%) | 37/237 (15.6) | 18/133 (13.5) | 19/104 (18.3) | 0.319 |
| XDR-TB, n (%) | 170/367 (46.3) | 81/151 (53.6) | 89/216 (41.2) | 0.019 |
| Previous exposure to anti-TB therapy, years | 2.53 | 2.77 | 2.43 | 0.835 |
| Median (IQR) exposure to linezolid, days | 340 (63.5-690.0) | 618 (150.0-690.0) | 224 (63.5-480.0) | 0.062 |
MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis; LNZ, linezolid.